Founded in January 19th, 2010, Institute of pharmaceutical science (IPS) is a platform for comprehensive pharmaceutical research and new drug development. Integrating the resources of drug research in CPU, IPS seeks to establish a flow path of drug development. IPS contains 6 functional parts, including the State Key Laboratory of Natural Medicines, as well as 5 research centers (New Drug Research Center, Jiangsu Key Laboratory of Anti-Metabolic Diseases Drugs， Jiangsu Key laboratory of Pharmacokinetics , New Drug Screening Center， New Drug Safety Evaluation Research Center and Analysis & Test Center). To concatenate all stages in drug development, IPS implements top-level design, centralized planning and unified management towards the above laboratories. We try to improve the efficiency in pharmaceutical research and ultimately accomplish the success of the development of new drug.
There are totally 93 faculty members in IPS, including 2 academicians, 4 chair professors of Yanstse River Scholars Programme, 3 winners of the National Science Fund for Distinguished Young Scholar, 2 winners of the Jiangsu Province Science Fund for Distinguished Young Scholar, 12 members of Program of New Century Excellent Talents in University, 20 senior teachers, 28 vice senior teachers, 18 junior teachers, 17 doctoral supervisors and 31 master student supervisors.
To date, IPS has launched 90 national major new drug creation specials and other national grants. Up to now, we have obtained 7 new drug certificates and production approvals, with more than 133 patents and over 550 SCI papers published. We promote the close connection between innovative technology and industrial incubation for accelerating the integration, industrialization and internationalization of scientific and technological achievements in new drug research. We extensively and strategically cooperate with several companies, such as Shanghai Institute of Materia Medica of Chinese Academy of Sciences, Nanjing University, Shanghai Pharmaceuticals Holding Co. Ltd, China Shijiazhuang Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Lianyungang Kangyuan Pharmaceutical Co. Ltd., Yangtze River Pharmaceutical Group, Yunnan Baiyao Group, Simcere Pharmaceutical Group, C&O Pharmaceutical Technology (holding) Limited, Virginia Commonwealth University.
IPS will strive to serve as the center of scientific research in